The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk patients with type 2 diabetes (T2D), chronic kidney disease (CKD), and ...

(NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for ...

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced significant findings about ATI-2138, a novel investigational drug ...

That is the number of women in the United States that have reported completed or attempted rape during their lifetime — 21% of the population, about 1 in every 5 women [1].

This new agent, like the other DPP-4 inhibitors, has a mechanism of action that affects both pancreatic ß-cell survival as well as ß-cell secretory function. These medications do not incite ...

An investigational therapy significantly shrank lung cancer tumors that are notoriously resistant to treatment by encouraging ...

Shares in the UK's IP Group slid today after it revealed that an arthritis drug in development at one of its portfolio ...

The leading Metastatic Pancreatic Cancer Companies such as Xencor, MEI Pharma, Celldex Therapeutics, TG Therapeutics, ...

Regeneron Pharmaceuticals' fourth quarter results beat my and Wall Street analysts' expectations. See why REGN stock is a top ...

A new study found that a drug recently approved to treat type 2 diabetes and kidney disease in patients with additional ...

Subscribe to Sky Sports to watch live, or stream on NOW. You'll need a subscription that includes Sky Sports Action.